Crewe Advisors’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Crewe Advisors’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7	Closed	-$27	–	818
2024 Q3	$27	Hold	7	–	–	﹤0.01%	712
2024 Q2	$69	Hold	7	–	–	﹤0.01%	934
2024 Q1	$547	Hold	7	–	–	﹤0.01%	905
2023 Q4	$1.29K	Hold	7	–	–	﹤0.01%	309
2023 Q3	$5.11K	Hold	7	–	–	﹤0.01%	285
2023 Q2	$33.2K	Hold	7	–	–	﹤0.01%	304
2023 Q1	$19.2K	Hold	7	–	–	﹤0.01%	443
2022 Q4	$18.9K	Hold	7	–	–	﹤0.01%	435
2022 Q3	$29K	Hold	7	–	–	0.01%	402
2022 Q2	$19K	Buy	+7	New	+$18.2K	﹤0.01%	440

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

VWWMG

Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $174M AUM 15.31% 1-Year Est. Return

Crewe Advisors's SEEL Position: Q4 2024 in Review

Crewe Advisors sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 7 shares — an estimated $27 sold.

Crewe Advisors first reported a position in SEEL in Q2 2022 and held it in 10 quarters. The position peaked at $33.2K in Q2 2023. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.

Crewe Advisors reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Crewe Advisors sold 7 Seelos Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $27.
Crewe Advisors first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2022 and held it in 10 quarters.
Crewe Advisors's Seelos Therapeutics, Inc. Common Stock position peaked at $33.2K in Q2 2023.
2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Crewe Advisors's 13F filing for Q4 2024, filed 27 Jan 2025.